Lumito presents at Analyst Group’s and InFront Direkt Studios’ capital markets day
Lumito AB (publ) ("Lumito" or the "Company") will, on Wednesday, 11 March 2026, present the Company, current status and the way forward at a capital markets day arranged by Analyst Group together with InFront Direkt Studios.
Capital markets day
Date and time: 11 March 2026, 9:00-13:00 (Lumito's presentation is at 10:20).
Location: online, follow this link to attend.
The event will be filmed and made available on the Company's website as well as on Analyst Group’s and InFront Direkt Studios’ websites afterwards.
For further information, please contact:
Sanna Wallenborg, CEO Lumito
E-mail: sw@lumito.se
Ph: +4670-870 01 68
About Lumito
Lumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center. www.lumito.se/en/
The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.
Bifogade filer